Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Burcon NutraScience Corp    BU   CA1208311029

BURCON NUTRASCIENCE CORP

(BU)
  Report  
Delayed Quote. Delayed Toronto Stock Exchange - 09/17 03:59:59 pm
1.48 CAD   +3.50%
11:20aBURCON NUTRASCIENCE CORP. : Burcon Updates on Development Activities
EQ
08:05aBurcon Updates on Development Activities
NE
09/09Big Ag wants a cut of booming fake-meat market
RE
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Upcoming events on BURCON NUTRASCIENCE CORP
09/17/19 | 01:00pm Annual General Meeting
02/13/20 Q3 2020 Earnings Release (Projected)
08/06/20 Q1 2021 Earnings Release (Projected)
Past events on BURCON NUTRASCIENCE CORP
07/02/19 FY 2019 Earnings Release
06/04/19 | 12:00pm LD Micro Invitational Conference
05/29/19 RIGHTS ISSUE: 1 new share @ 0.35 CAD for 1 existing share
09/06/18 | 01:00pm Annual General Meeting
Upcoming sector events for BURCON NUTRASCIENCE CORP
09/18/19 QIAGEN NV : Bank of America Merrill Lynch Global Health Care Conference
09/18/19 | 07:10am INCYTE CORPORATION : Bank of America Merrill Lynch Global Health Care Conference
09/18/19 | 09:30am BLUEBIRD BIO INC : European Pediatric Neurology Society Congress - Phase 2/3 Trial to Assess the Safety and Efficacy
09/18/19 | 09:30am BLUEBIRD BIO INC : European Pediatric Neurology Society Congress - An observational study of outcomes of Allogeneic Hem
More events
Past sector events for BURCON NUTRASCIENCE CORP
09/14/19 | 06:00pm IONIS PHARMACEUTICALS INC : Heart Failure Society of America Scientific Meeting
09/14/19 | 06:15pm ALNYLAM PHARMACEUTICALS, INC. : Heart Failure Society of America Scientific Meeting - Identifying Mixed Phenotype
09/14/19 | 06:15pm ALNYLAM PHARMACEUTICALS, INC. : Heart Failure Society of America Scientific Meeting - Risk Factors for Mortality in Patients with He
09/16/19 | 01:00pm ALNYLAM PHARMACEUTICALS, INC. : Investor Meeting - Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis
Annual publications
Annual results20192020 (e)2021 (e)2022 (e)
Sales
M CAD
Released
Forecast
Spread
0,04


0,09

1,64

6,70
Operating income
(EBITDA)
M CAD
Released
Forecast
Spread



-4,53

-3,11

6,25
Operating profit
(EBIT)
 
Released
Forecast
Spread








Pre-Tax Profit
(EBT)
M CAD
Released
Forecast
Spread





-2,99

2,00
Net income
M CAD
Released
Forecast
Spread





-2,99

6,40
EPS
 CAD
Released
Forecast
Spread
-0,11


-0,06

-0,03

0,07
Announcement Date07/02/2019

Assessed data source
© 2019 S&P Global Market Intelligence
© 2019 Factset
Net sales (Year) - Rate of surprise
Operating profit (Year) - Rate of surprise
EPS (Year) - Rate of surprise